Navigation Links
Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
Date:6/6/2011

SUNNYVALE, Calif., June 6, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced data from the oral presentation of the Phase IB/II study of the Btk inhibitor, PCI-32765, in chronic lymphocytic leukemia / small cell lymphocytic lymphoma (CLL/SLL) at the 2011 American Society of Clinical Oncology Annual Meeting. The company will also provide a clinical development program update for the Btk Inhibitor, PCI-32765.  The update will include 1) efficacy from the Phase IA trial of PCI-32765 in B-cell malignancies including mantle cell lymphoma, follicular lymphoma and diffuse large B-cell lymphoma and 2) a status update for ongoing PCI-32765 clinical studies, and 3) an update on future clinical trials including program expansion opportunities in follicular lymphoma and multiple myeloma.  The company will also provide information on the Non-Hodgkins Lymphoma (NHL) market. An investor conference call to discuss the clinical trial results and other company updates will be hosted today at 4:30pm ET, further information is provided below.  Slide presentations will be posted on the Pharmacyclics website including the ASCO presentation of the Phase IB/II study results and the Investor Relations presentation.  

Data Results from the Phase IB/II Study in CLL/SLL as presented at ASCO

The oral presentation, titled "Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small cell lymphocytic lymphoma (CLL/SLL): Interim results of a Phase Ib/II study" was being presented by John C. Byrd, MD today.  The presentation included interim data from a single-agent, multi-cohort study evaluating PCI-32765 in CLL/SLL patients with relapsed/ refractory disease or with treatment-naive disease who were 65 years of age or older.  A daily oral dose of 420mg was tested
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Calif. , July 31, 2015  Xencor, Inc. ... engineered monoclonal antibodies for the treatment of autoimmune diseases, ... appointment of Yujiro S. Hata to its ... experience in business and corporate development is a tremendous ... Ph.D., president and chief executive officer of Xencor. "Xencor ...
(Date:7/31/2015)... HYDERABAD, India , July 31, 2015 /PRNewswire/ ... Billing and CRM solutions for video, data and cloud ... (PoC) with a leading pharma giant for Internet ... managing different IoT applications offered on subscription model. ... Pharma giant is striving for business ...
(Date:7/30/2015)... COLUMBUS, Ohio, July 30, 2015 Mettler-Toledo International ... results for 2015.  Provided below are the highlights: ... the quarter compared with the prior year. Reported sales ... in the quarter. , Net earnings per diluted ... in the prior-year period. Adjusted EPS was $2.80 , ...
Breaking Medicine Technology:Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14
(Date:7/31/2015)... Indianapolis, Ind. (PRWEB) , ... August 01, 2015 , ... ... of the Global Advisory Panel on the Future of Nursing (GAPFON) 20-21 July 2015 ... were invited to participate in this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... players to know in predictive health analytics , Jvion continues to disrupt ... firm creates predictive software that targets patient and population level illness to drive ...
(Date:7/31/2015)... ... ... There’s no better way to enjoy the summer weather than by being outside ... making July the most appropriate to be National Hot Dog Month. King Kullen honors ... next cookout different than the ones in the past. Celebrate National Hot Dog Month ...
(Date:7/31/2015)... ... July 31, 2015 , ... M3 USA MDLinx.com, source of ... three new Board Exam Courses. , The additions of Gastroenterology, Pulmonology and Allergy/Immunology ... from MDLinx makes preparing for the exam easy and painless. MDLinx offers thousands ...
(Date:7/31/2015)... NV (PRWEB) , ... July 31, 2015 , ... Well-known ... is now offering wedding cakes with custom designs, making life just a ... deliver beautifully designed wedding cakes for each customer who orders one. , The bakery ...
Breaking Medicine News(10 mins):Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2
... /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), ... strategy and its unique niche in the drug development ... the latest generation of biotherapeutic technologies that can cure ... on prostate and breast cancers, GENova has acquired a ...
... , , MURRIETA, Calif., Sept. ... ABTTC Inc. division provides drug and alcohol rehabilitation and a ... of accreditation, announced today that Jerrod Menz, Forterus Vice President ... and Jim Fent, Executive Vice President, will be interviewed on ...
... ... Nursing Reference Center™ and Patient Education Reference Center™ Available online at www.ebscohost.com/flu . ... , ... (PRWEB) September 9, 2009 -- Concerns about Pandemic H1N1 and the upcoming flu season ...
... ... as well as cosmetic and sedation dentistry, announces the addition of it,s sister practice, ... ... Dentistry, led by Dr. Robert L. Williamson III is pleased to announce the addition ...
... Democratic National Committee Members To Gather September 10-12 at ... Highlight Meeting , , WASHINGTON, Sept. 9 ... meet this Thursday, September 10 through Saturday, September 12 at ... meeting on Friday, members will hear a major speech from ...
... JACKSONVILLE, Fla., Sept. 8 Sinapis Pharma announces that ... injury treatment data at the Rodman & Renshaw Annual Global Investment ... September 11, 2009, at 3:15 PM ET. Sinapis has discovered ... of an FDA-approved drug that will be in clinical development in ...
Cached Medicine News:Health News:GENova discusses development of new anti-cancer biotechs potentially worth $400 Million per annum 2Health News:GENova discusses development of new anti-cancer biotechs potentially worth $400 Million per annum 3Health News:Forterus Inc. Executives to Be Interviewed on VoiceAmerica 2Health News:EBSCO Publishing Makes Evidence-Based Flu Resources Freely Available 2Health News:EBSCO Publishing Makes Evidence-Based Flu Resources Freely Available 3Health News:Raleigh Comprehensive and Cosmetic Dentistry Announces Addition of New Practice to Raleigh Dentist Family 2Health News:Details of DNC Fall Meeting in Austin 2
... Iodine 'Prep' solutions are ... mucous membrane preparation prior ... Povidone Iodine 'Scrub' solutions ... surfactants. Each is effective ...
... BETADINE Solution is ... 10% povidone-iodine. It is ... that kills gram-positive and ... resistant organisms), as well ...
... topical gel contains 10% Povidone Iodine USP, ... As a pre-operative prep, Povidone Iodine Gel ... solutions under the patient, thus reducing the ... also approved as a one step gel ...
... Iodine Prep Solution is appropriate for ... wet soak or spray); disinfecting of ... treatment of lacerations and abrasions. It ... agent in hospital and office procedures, ...
Medicine Products: